Mode of Action of Idarucizumab
(Praxbind®)

Document ID: MPR-PH-100003

01/06/2018

Author: Boehringer Ingelheim


Dabigatran inhibits the formation of blood clots by specifically binding to thrombin

123,000
Views

100k 340

Production date: May 2019